PDCD1 and familial pancreatic carcinoma: Selection of currently ongoing clinical trials evaluating CTLA4 or/and PD1/PD-L1 checkpoint blockade in combination with untargeted and targeted options including other immunotherapeutic approaches for pancreatic cancer as indicated.